An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with metastatic castrate-resistant prostate cancer

Principal Investigator

Dr Philip Camilleri

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1011550